Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul;16(7):895-901.
doi: 10.1517/14712598.2016.1170805. Epub 2016 Apr 8.

Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors

Julius Strauss  1 , Ravi A Madan  1 , James L Gulley  1
Affiliations
Review

Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors

Julius Strauss et al. Expert Opin Biol Ther. 2016 Jul.

Abstract

Introduction: Over the past few years, trials evaluating immunotherapies, particularly immune checkpoint inhibitors, have revolutionized the standard model of cancer treatment, demonstrating significant antitumor responses and improved clinical outcomes across a wide array of tumors types. Yet, despite these compelling data, a major limitation has been that only a fraction of patients mount a response to single-agent immune checkpoint inhibition. However, a growing amount of preclinical and clinical data suggests that combining immune checkpoint inhibition, either with other immune checkpoint inhibitors or with therapeutic cancer vaccines, has the potential to improve the proportion of patients seeing long-term durable responses with these therapies.

Areas covered: We have reviewed the reported data on immune checkpoint inhibition as monotherapy and as combination therapy with other immune checkpoint inhibitors or therapeutic cancer vaccines. Data is reviewed on agents with FDA approval or breakthrough designation as of the writing of this manuscript.

Expert opinion: Particular focus is given to the combination of immune checkpoint inhibitors and therapeutic cancer vaccines which has the potential to increase efficacy compared to single agent immune checkpoint inhibition with minimal added toxicity.

Keywords: Immune checkpoint inhibitors; immunogenic intensification; therapeutic cancer vaccines.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

References

    1. Mahoney KM, Atkins MB. Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park). 2014;28(Suppl 3):39–48. - PubMed
    1. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723. doi:10.1056/NEJMoal003466. - DOI - PMC - PubMed

    2. • This phase III trial was the first to show an overall survival benefit for immune checkpoint inhibition in solid tumors and led to FDA approval of ipilimumab for advanced melanoma.

    1. Weber J, Minor D, D’Angelo S, et al. A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy. Ann Oncol. 2014;25(suppl4):abstrLBA3-PR.

    2. • This trial led to FDA approval of nivolumab for advanced melanoma after prior CTLA-4 therapy.

    1. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–330. doi:10.1056/NEJMoal412082. - DOI - PubMed

    2. • This trial led to FDA approval of nivolumab for untreated advanced melanoma.

    1. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135. doi:10.1056/NEJMoal504627. - DOI - PMC - PubMed

    2. • This trial led to FDA approval of nivolumab for advanced squamous NSCLC.

MeSH terms

LinkOut - more resources